Brainstorm Cell Debt
| GHDN Stock | EUR 2.69 0.00 0.00% |
Brainstorm Cell Ther has over 3.04 Million in debt which may indicate that it relies heavily on debt financing. . Brainstorm Cell's financial risk is the risk to Brainstorm Cell stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Brainstorm Cell's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Brainstorm Cell's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Brainstorm Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Brainstorm Cell's stakeholders.
For most companies, including Brainstorm Cell, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Brainstorm Cell Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Brainstorm Cell's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Brainstorm Cell's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Brainstorm Cell is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Brainstorm Cell to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Brainstorm Cell is said to be less leveraged. If creditors hold a majority of Brainstorm Cell's assets, the Company is said to be highly leveraged.
Brainstorm |
Brainstorm Cell Ther Debt to Cash Allocation
Many companies such as Brainstorm Cell, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Brainstorm Cell Therapeutics has accumulated 3.04 M in total debt with debt to equity ratio (D/E) of 934.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Brainstorm Cell Ther has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Brainstorm Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Brainstorm Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brainstorm Cell Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brainstorm to invest in growth at high rates of return. When we think about Brainstorm Cell's use of debt, we should always consider it together with cash and equity.Brainstorm Cell Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Brainstorm Cell's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Brainstorm Cell, which in turn will lower the firm's financial flexibility.Brainstorm Cell Corporate Bonds Issued
Most Brainstorm bonds can be classified according to their maturity, which is the date when Brainstorm Cell Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understaning Brainstorm Cell Use of Financial Leverage
Brainstorm Cell's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Brainstorm Cell's total debt position, including all outstanding debt obligations, and compares it with Brainstorm Cell's equity. Financial leverage can amplify the potential profits to Brainstorm Cell's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Brainstorm Cell is unable to cover its debt costs.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BRAINSTORM operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 31 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out the analysis of Brainstorm Cell Fundamentals Over Time. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.